The end is near





I would disagree with that. Fiasp and Xultophy are truly innovative products that didn't catch on with insurers and primary care providers in the US. We have several more products that we won't launch because of the dysfunctional HC system in the states. Look at the success of Soliqua, a completely inferior product. We handed that to Sanofi.